AN INCREASED INTEREST in the IPO market by biotechnology companies has meant extra work for Arnall Golden Gregory partner Alan G. Minsk.
One of Minsk’s clients, Cadence Pharmaceuticals Inc., last month held an initial public offering. Cadence’s was one of several IPOs in the last month by drug-makers. Others that have entered the public markets include Achillion
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
